Unlike traditional tumor vaccines, IGV-001 is prepared by mixing tumor tissue removed from the patient’s brain with an insulin-like growth factor 1 receptor antisense oligonucleotide (IMV-001), which inhibits tumor growth. Here, IGF1R is linked to neoplasm.